Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

In addition to dry skin, dryness of the mucosae (eyes, vagina, mouth or nose) may also occur in EGFRI-treated patients.1,2,3

Furthermore, conjunctivitis can be seen, either due to dryness (Xerophthalmia) or to mechanical irritation by trichomegalic eyelashes (conjunctivitis).2 Dry mouth, Aphthous stomatitis or a geographic tongue may be encountered in the oral mucosa.3,4 The genitalia are occasionally involved with dry vulvovaginitis (especially in postmenopausal women) or Balanitis.5

Incidence: Common.6,7,8,9,10

Onset: Some weeks to months after treatment initiation.

Resolution: Some weeks following completion of EGFRI treatment.

Conjunctivitis and Blepharitis

ICD10 codes:    

  • Y43.8 Other drugs, medicaments and biologicals, primarily systemic substances causing adverse effects in therapeutic use, not elsewhere classified.
  • H10.9 Conjunctivitis, unspecified.
  • H19.3 Keratoconjunctivitis sicca.

Typical clinical presentations of conjunctivitis and Blepharitis can be viewed at the bottom of the page.


ICD10 code:

  • N76.8 Other specified inflammation of vagina and vulva.

Typical clinical presentation of vulvitis can be viewed at the bottom of the page.


ICD10 code:

  • N51.2 Balanitis in diseases classified elsewhere  

Typical clinical presentation of Balanitis can be viewed at the bottom of the page.

Oral mucositis

ICD10 code:

  • K91.8 Other postprocedural disorders of digestive system, not elsewhere classified.

Typical clinical presentation of oral mucositis can be viewed at the bottom of the page.


1Segaert S & Van Cutsem E. Ann Oncol 2005; 16: 1425-1433.
2Melichar B & Nemcová I. Eur J Cancer Care (Engl) 2007; 16: 439-443.
3Busam KJ et al. Br J Dermatol 2001; 144: 1169-1176.
4Segaert S & Van Cutsem E. Oncology (Williston Park) 2007; 21: 22-26.
5Segaert S et al. Eur J Cancer 2009; 45(Suppl 1): 295-308.
6European Medicine Agency. Tarceva® (erlotinib) Summary of Product Characteristics 2009.
7European Medicine Agency. Iressa® (gefitinib) Summary of Product Characteristics 2009.
8European Medicine Agency. Erbitux® (cetuximab) Summary of Product Characteristics 2009.
9European Medicine Agency. Vectibix® (panitumumab) Summary of Product Characteristics 2009.
10European Medicine Agency. Tyverb® (lapatinib) Summary of Product Characteristics 2010.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings